Feops
Cutting-edge technology that creates digital twins from cardiac scans. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€24—36m (Dealroom.co estimates Sep 2017.)
Company register number 0817.146.806
Ghent East Flanders (HQ)
- hard tech
- biotechnology
- horizon europe
- sustainable development goals
- analytics
- core ai
- spinout
- ai applications
- eit ecosystem
- surgery
- cardiology
- non-invasive
- tech for hospitals & clinics
- health it
- tech for medical professionals
- physician support tools
- eicfund
- clinical decision support
- eic
- surgical equipment
- medical education
- medical data
- digital twin
- treatment assistance
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| EBITDA | (<1m) | (<1m) | (<1m) | <1m | <1m | (1.2m) | - |
| Profit | (<1m) | (1.2m) | (1.4m) | (<1m) | (<1m) | (2.1m) | (2.4m) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
€1.3m | Series A | ||
€50.0k | Grant | ||
* | €6.0m | Series B | |
€3.2m | Grant | ||
* | €3.3m | Convertible | |
* | N/A | Acquisition | |
| Total Funding | €13.9m | ||
Recent News about Feops
EditMore about Feops
EditDeveloper of a cardiac imaging technology designed to improve and expand personalized treatment for patients with structural heart disease. The company offers AI-enabled anatomical analyses to generate data-driven insights to improve transcatheter valve procedures based on personalized computer simulations, enabling healthcare professionals to improve both procedure efficiency and clinical outcomes.
Keywords: Pharmaceuticals and Biotechnology, Cardiovascular Intervention, Computer Simulation, Invasive Device, Patient-Specific Insights, Structural Heart Intervention, Transcatheter Heart Valve, Transcatheter Valves System.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.